Literature DB >> 13680098

Chromosomally encoded gyrase inhibitor GyrI protects Escherichia coli against DNA-damaging agents.

Monalisa Chatterji1, Sugopa Sengupta, Valakunja Nagaraja.   

Abstract

DNA gyrase, a type II topoisomerase, is the sole supercoiling activity in the cell and is essential for cell survival. There are two proteinaceous inhibitors of DNA gyrase that are plasmid-borne and ensure maintenance of the plasmids in bacterial populations. However, the physiological role of GyrI, an inhibitor of DNA gyrase encoded by the Escherichia coli genome, has been elusive. Previously, we have shown that GyrI imparts resistance against microcin B17 and CcdB. Here, we find that GyrI provided partial/limited protection against the quinolone class of gyrase inhibitors but had no effect on inhibitors that interfere with the ATPase activity of the enzyme. Moreover, GyrI negated the effect of alkylating agents, such as mitomycin C and N-methyl- N-nitro- N-nitrosoguanidine, that act independently of DNA gyrase. Hence, in vivo, GyrI appears to be involved in reducing DNA damage from many sources. In contrast, GyrI is not effective against lesions induced by ultraviolet radiation. Furthermore, the expression of GyrI does not significantly alter the topology of DNA. Thus, although isolated as an inhibitor of DNA gyrase, GyrI seems to have a broader role in vivo than previously envisaged.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13680098     DOI: 10.1007/s00203-003-0598-4

Source DB:  PubMed          Journal:  Arch Microbiol        ISSN: 0302-8933            Impact factor:   2.552


  14 in total

1.  Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase.

Authors:  John H Tran; George A Jacoby; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Depletion of RNase HI activity in Escherichia coli lacking DNA topoisomerase I leads to defects in DNA supercoiling and segregation.

Authors:  Valentine Usongo; Flora Nolent; Patrick Sanscartier; Cynthia Tanguay; Sonia Broccoli; Imad Baaklini; Karl Drlica; Marc Drolet
Journal:  Mol Microbiol       Date:  2008-06-28       Impact factor: 3.501

3.  The aminoglycoside antibiotic kanamycin damages DNA bases in Escherichia coli: caffeine potentiates the DNA-damaging effects of kanamycin while suppressing cell killing by ciprofloxacin in Escherichia coli and Bacillus anthracis.

Authors:  Tina Manzhu Kang; Jessica Yuan; Angelyn Nguyen; Elinne Becket; Hanjing Yang; Jeffrey H Miller
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

Review 4.  DNA repair and genome maintenance in Bacillus subtilis.

Authors:  Justin S Lenhart; Jeremy W Schroeder; Brian W Walsh; Lyle A Simmons
Journal:  Microbiol Mol Biol Rev       Date:  2012-09       Impact factor: 11.056

5.  The SOS Regulatory Network.

Authors:  Lyle A Simmons; James J Foti; Susan E Cohen; Graham C Walker
Journal:  EcoSal Plus       Date:  2008-07-25

Review 6.  Plasmid-mediated quinolone resistance: a multifaceted threat.

Authors:  Jacob Strahilevitz; George A Jacoby; David C Hooper; Ari Robicsek
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 7.  Exploiting bacterial DNA gyrase as a drug target: current state and perspectives.

Authors:  Frédéric Collin; Shantanu Karkare; Anthony Maxwell
Journal:  Appl Microbiol Biotechnol       Date:  2011-09-09       Impact factor: 4.813

8.  Glutamate racemase from Mycobacterium tuberculosis inhibits DNA gyrase by affecting its DNA-binding.

Authors:  Sugopa Sengupta; Meera Shah; Valakunja Nagaraja
Journal:  Nucleic Acids Res       Date:  2006-10-04       Impact factor: 16.971

Review 9.  TEX264 at the intersection of autophagy and DNA repair.

Authors:  John Fielden; Marta Popović; Kristijan Ramadan
Journal:  Autophagy       Date:  2021-03-17       Impact factor: 16.016

10.  Whole genome sequence analysis of the first Australian OXA-48-producing outbreak-associated Klebsiella pneumoniae isolates: the resistome and in vivo evolution.

Authors:  Björn A Espedido; Jason A Steen; Helen Ziochos; Sean M Grimmond; Matthew A Cooper; Iain B Gosbell; Sebastiaan J van Hal; Slade O Jensen
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.